GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » Gross Profit
中文

Curis (CRIS) Gross Profit : $9.81 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

Curis Gross Profit Definition

Curis's gross profit for the three months ended in Dec. 2023 was $2.64 Mil. Curis's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $9.81 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Curis's gross profit for the three months ended in Dec. 2023 was $2.64 Mil. Curis's Revenue for the three months ended in Dec. 2023 was $2.70 Mil. Therefore, Curis's Gross Margin % for the quarter that ended in Dec. 2023 was 98.00%.

Curis had a gross margin of 98.00% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Curis was 97.89%. The lowest was 94.60%. And the median was 94.99%.


Curis Gross Profit Historical Data

The historical data trend for Curis's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.50 10.30 10.12 9.91 9.81

Curis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.82 2.27 2.12 2.77 2.64

Competitive Comparison

For the Biotechnology subindustry, Curis's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis Gross Profit Distribution

For the Biotechnology industry and Healthcare sector, Curis's Gross Profit distribution charts can be found below:

* The bar in red indicates where Curis's Gross Profit falls into.



Curis Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Curis's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=10.023 - 0.212
=9.81

Curis's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=2.696 - 0.054
=2.64

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.81 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Curis's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.64 / 2.696
=98.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Curis  (NAS:CRIS) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Curis had a gross margin of 98.00% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Curis Gross Profit Related Terms

Thank you for viewing the detailed overview of Curis's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Curis (CRIS) Business Description

Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Executives
Jonathan B. Zung officer: CDO C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Kenneth I Kaitin director C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111
Martyn D Greenacre director 41 MOORES ROAD, FRAZER PA 19355
Robert Martell officer: Head of Research & Development 4 MAGUIRE ROAD, LEXINGTON MA 02421
Diantha Duvall officer: CFO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James E Dentzer director, officer: President & CEO C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
William Steinkrauss officer: VP, Finance & Treasurer, other: Principal Accounting Officer C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Fattaey Ali Ph.d. officer: President & COO C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Aurigene Discovery Technologies Ltd 10 percent owner 39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100
David Tuck officer: Sr. Vice-President C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421